FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

4D Molecular Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$12.29+0.15 (+1.24%)

Close on Oct 19, 2026

Market cap: $863.64M
P/E (TTM): –
Dividend yield: –

4D Molecular Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	60	149	249	52	153	277	50	–
Short-Term Investments	342	276	39	161	95	0	–	–
Cash & Short-Term Investments	514	425	288	214	248	277	50	–
Receivables	–	–	–	0	0.05	1.49	0.98	–
Prepaid Expenses & Other	10	10	8.36	6.96	8.46	4.44	1.88	–
Total Current Assets	413	435	297	221	256	283	53	–
Property, Plant & Equipment	15	20	20	22	14	5.07	5.05	–
Gross Property, Plant & Equipment	36	36	32	30	20	8.92	7.67	–
Accumulated Depreciation	-21	-17	-12	-7.73	-5.33	-3.84	-2.63	–
Long-Term Investments	111	81	11	4.91	68	0	–	–
Operating Lease Right-of-Use Assets	18	21	12	13	15	17	–	–
Other Long-Term Assets	9.19	4.26	0.68	1.08	0.60	0.60	0.68	–
Total Assets	567	560	340	262	353	288	58	–
Accounts Payable	11	4.39	3.52	3.32	4.76	1.79	1.74	–
Accrued Expenses	27	19	12	8.87	7.74	8.37	–	–
Current Portion of Leases	5.59	5.64	3.15	2.66	1.23	2.00	–	–
Deferred Revenue (Current)	0.36	0.26	0.27	0.88	2.60	6.59	5.86	–
Total Current Liabilities	44	29	19	16	16	17	13	–
Long-Term Debt	0	–	–	–	–	–	–	–
Long-Term Leases	16	19	12	13	15	16	–	–
Operating Lease Liabilities	21	25	15	16	16	18	–	–
Other Long-Term Liabilities	0.14	0.19	0.25	0.02	0.12	1.85	1.57	–
Total Liabilities	61	50	32	31	34	32	28	–
Total Debt	0	–	–	–	–	–	–	–
Preferred Stock	0	0	0	0	0	0	0	–
Common Stock	0.01	0.01	0.00	0.00	0.00	0.00	0.00	–
Additional Paid-In Capital	1,221	1,087	723	547	527	392	6.05	–
Retained Earnings	-716	-576	-415	-314	-207	-136	-79	–
Comprehensive Income & Other	0.73	0.23	0.02	-1.20	-0.42	0	–	–
Shareholders' Equity	506	511	308	231	319	256	-73	-28
Total Equity	506	511	308	231	319	256	-73	-28
Total Liabilities & Equity	567	560	340	262	353	288	58	–
Shares Outstanding(shares)	58	46	43	33	32	27	5.18	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -214.2%
Net margin: -194.7%
Return on equity, FY2025: -27.6%

Financial strength

Current ratio: 8.03
Debt to equity: 0.05
Debt to assets: 4.0%
Cash to current liabilities: 147.6%

Valuation

P/E ratio: –
Price to sales: 9.39
Price to book: 2.12
Dividend yield: –